These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 25596250)

  • 1. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
    Morishima Y; Kamisato C
    Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
    Honda Y; Morishima Y
    Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
    Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
    Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
    Siriez R; Evrard J; Dogné JM; Pochet L; Gheldof D; Chatelain B; Mullier F; Douxfils J
    Thromb Haemost; 2018 Jul; 118(7):1203-1214. PubMed ID: 29890519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
    Noguchi K; Morishima Y; Takahashi S; Ishihara H; Shibano T; Murata M
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):117-22. PubMed ID: 24911450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
    Siddiqui F; Hoppensteadt D; Jeske W; Iqbal O; Tafur A; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619847524. PubMed ID: 31088146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.
    Iba T; Emmi M; Hiki M; Nagayama M; Aihara K; Tabe Y; Yuri M; Ohsaka A
    Int J Hematol; 2016 Jun; 103(6):665-72. PubMed ID: 26984594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
    Sinegre T; Zlobecki M; Doré E; Pereira B; Grèze V; Lebreton A
    Thromb Res; 2019 Jun; 178():112-118. PubMed ID: 31005667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
    Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
    Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
    Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
    Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
    Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.